ArticleBiology methods & protocols2018
Construction of an overexpression library for
Article in Biology methods & protocols, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- An adenylyl cyclase switch reroutes carbon from growth to virulence lipids inbioRxiv : the preprint server for biology · 2026Article
- Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023Review
- High-throughput functional genomics: A (myco)bacterial perspective.Molecular microbiology · 2023Review
- Deletion of Rv2571c confers resistance to arylamide compounds inAntimicrobial agents and chemotherapy · 2023Article
- Low-cost anti-mycobacterial drug discovery using engineered E. coli.Nature communications · 2022Article
- Biology of antimicrobial resistance and approaches to combat it.Science translational medicine · 2020Review
- Biosynthesis of Galactan inAntibiotics (Basel, Switzerland) · 2020Review
- Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes.Nature communications · 2019Article
- Identification of Enolase as the Target of 2-Aminothiazoles inFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
There is a pressing need to develop novel anti-tubercular drugs. High-throughput phenotypic screening yields chemical series that inhibit bacterial growth. Target identification for such series is challenging, but necessary for optimization of target engagement and the development of series into clinical drugs. We constructed a library of recombinant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.